BG00012

ApprovedSmall molecule

BG00012 is one of 104 small molecule programs targeting Relapsing-Remitting Multiple Sclerosis. It is currently in Approved.

Indications

Total Trials

Active Trials

103

Competitors

Pipeline

Status by Indication[3][1]

Indication

Relapsing-Remitting Multiple SclerosisActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

Multiple SclerosisActive, not recruiting

FlushingActive, not recruiting

Relapsing-Remitting Multiple SclerosisPhase 3

Active, not recruiting

Rheumatoid ArthritisPhase 2

Active, not recruiting

Multiple SclerosisApproved

Active, not recruiting

FlushingPhase 3

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

BG00012

Biogen

Approved

1 2

Rituxan

Roche

Preclinical

61 3

Orencia

Bristol-Myers Squibb

Preclinical

47 4

Enbrel

IImmunex

Preclinical

64 5

Remicade

OOrganon and Co

Preclinical

43 6

Kevzara

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

14 7

Ilaris

Novartis

Preclinical

3 8

Celexa

AbbVie

Preclinical

1 9

Zelhou

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

7 10

Cataflam

Novartis

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Relapsing-Remitting Multiple Sclerosis2 trials

Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis

Completed· Biogen logo

Biogen·Phase 3·NCT00451451·1,417 enrolled

Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis

Completed· Biogen logo

Biogen·Phase 3·NCT00420212·1,234 enrolled

Phase 11 trial

Phase 1 Study to Evaluate the PK, Safety, and Tolerability of BG00012 in Chinese, Japanese, and Caucasian Healthy Volunteers

Completed· Biogen logo

Biogen·Phase 1·NCT01453426·71 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of BG00012 in MS

Completed· Biogen logo

Biogen·Phase 2·NCT00168701·260 enrolled

Oral1 trial

A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS

Completed· Biogen logo

Biogen·Phase 1·NCT00837785·48 enrolled

Flushing1 trial

Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate

Completed· Biogen logo

Biogen·Phase 3·NCT01568112·173 enrolled

4 more indications

Biomarkers1 trial

Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers

Completed·MMultiple Sclerosis Center of Northeastern New York·Phase 4·NCT02683863·20 enrolled

Multiple Sclerosis1 trial

Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States

Completed· Biogen logo

Biogen·Phase 4·NCT01873417·237 enrolled

Tics1 trial

Pharmacokinetics Profile Study of BG00012 Standard Formulation and BG00012 Active Pharmaceutical Ingredient

Completed· Biogen logo

Biogen·Phase 1·NCT01069913·14 enrolled

Rheumatoid Arthritis1 trial

Efficacy and Safety Study of BG00012 With Methotrexate in Patients With Active Rheumatoid Arthritis

Completed· Biogen logo

Biogen·Phase 2·NCT00810836·153 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for BG00012. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BG00012 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BG00012. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Biogen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Biogen

BG00012

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Relapsing-Remitting Multiple Sclerosis2 trials

Phase 11 trial

Efficacy and Safety1 trial

Oral1 trial

Flushing1 trial

Biomarkers1 trial

Multiple Sclerosis1 trial

Tics1 trial

Rheumatoid Arthritis1 trial

References

Drug Info

Quick Facts

Related News